April 2014
Volume 55, Issue 13
ARVO Annual Meeting Abstract  |   April 2014
Influence of the neuroprotective drug memantine on organ-cultured diabetic or Alzheimer’s disease retina
Author Affiliations & Notes
  • Lilla Knels
    Anatomy, TU Dresden, Dresden, Germany
  • Claudia Knels
    Anatomy, TU Dresden, Dresden, Germany
  • Jana Loeffler
    Anatomy, TU Dresden, Dresden, Germany
  • Cornelia Schroeder
    Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany
  • Richard Funk
    Anatomy, TU Dresden, Dresden, Germany
    CRTD Center for Regenerative Therapies, Dresden, Germany
  • Monika Valtink
    Anatomy, TU Dresden, Dresden, Germany
  • Footnotes
    Commercial Relationships Lilla Knels, None; Claudia Knels, None; Jana Loeffler, None; Cornelia Schroeder, None; Richard Funk, None; Monika Valtink, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 1349. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Lilla Knels, Claudia Knels, Jana Loeffler, Cornelia Schroeder, Richard Funk, Monika Valtink; Influence of the neuroprotective drug memantine on organ-cultured diabetic or Alzheimer’s disease retina. Invest. Ophthalmol. Vis. Sci. 2014;55(13):1349.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: Alzheimer’s disease (AD) is characterized by amyloidogenic processing of the amyloid precursor protein (APP) and subsequent neuronal cell death. Glyoxal induces advanced glycation end products (AGEs) which result in diabetic metabolism. We investigated whether AGEs affect APP processing in the retina, and if the known AD drug memantine can diminish or prevent the formation of AGEs and/or can affect amyloidogenic APP processing via the β-secretase pathway.

Methods: AGEs and β-amyloid plaques were induced in retina explants from C57BL/6 (wt) mice by applying 1mmol/l glyoxal. Additionally, retina explants were treated with 10 µmol/l memantine. Retina explants of double transgenic SwAPP/Psen1d9 mice (AD model) were cultured with or without memantine. Explants were analyzed by Western blotting (WB), RT-PCR and immunohistochemistry (IHC), for AD proteins (APP, cleavage products sAPPα/β, β-amyloids, α-/β-secretases), apoptosis and stress markers (AIF, HO-1, Bax, CML), and GFAP after up to 5days cultivation. Explants were further analyzed by ELISA for beta-amyloid production.

Results: Glyoxal increased HO-1 and Bax mRNA levels, but not APP, TACE, BACE, and GFAP mRNA levels, in wt mouse retina. Additional treatment with memantine did not influence APP, TACE, BACE, HO-1, or GFAP, but decreased Bax expression. Memantine could reduce glyoxal-induced AGEs (CML), as seen in WB, while AIF and APP levels remained stable independent of glyoxal or memantine treatment. Glyoxal further induced Amyloid-β 40/42 deposition in the inner nuclear layer (INL) and decreased GFAP levels in Müller cells, as shown by IHC. Memantine could mitigate glyoxal-induced plaque formation in the INL. In the AD model, WB analyzes revealed enhanced APP and β-amyloid levels compared to control (wt) retinas. Here, memantine reduced soluble sAPPβ in retinal culture supernatants. Levels of stress or apoptosis proteins remained unchanged.

Conclusions: Memantine is non-toxic to the retina and might protect cells against glyoxal-induced damage by reducing the formation of AGEs. It may also interfere with the amyloidogenic processing of APP, hence representing a possible medication to prevent retinal damage in AD.

Keywords: 695 retinal degenerations: cell biology • 499 diabetic retinopathy • 690 retina: neurochemistry  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.